查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2094559

血液篩檢市場－2026-2032年全球市場預測

Blood Screening Market - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，血液篩檢市場將成長至 65 億美元，複合年成長率為 9.07%。

主要市場統計數據
基準年 2025 35.4億美元
預計年份：2026年 38.5億美元
預測年份 2032 65億美元
複合年成長率 (%) 9.07%

血液篩檢執行摘要

血液篩檢是輸血安全、感染疾病監測、產前保健、癌症治療支持、器官移植和公共衛生計畫的重要支柱。此領域涵蓋血清學檢測、核酸檢測、免疫血液學、血液學篩檢、分子診斷、病原體減少支持和捐血合格評估。持續的需求推動著血液篩檢的發展，這些需求包括預防輸血相關感染疾病、提高疾病早期檢出率、加強血庫品管體係以及支持具有韌性的醫療基礎設施。行業重點包括更快的檢測結果、更高的分析靈敏度、自動化的大批量工作流程、標準化的品管以及符合不斷變化的監管和認證要求。此外，血液篩檢計畫正日益與數位健康記錄、實驗室資訊系統、捐血管理平台和公共衛生報告網路相整合，從而建立一個更緊密整合的生態系統，以實現可追溯性、血液警戒和基於風險的決策。國際和國家公共衛生機構的指南一貫強調，安全、品質有保證的血液和血液成分對於醫療保健至關重要，重申了在醫院、血站和診斷檢查室進行可靠的血液篩檢的戰略重要性。

血液篩檢領域的變革性變化

在血液篩檢領域，一場結構性變革正在進行，從被動檢測轉向基於風險的整合式數位篩檢模式。檢查室和血站正在採用自動化分析儀、能夠以一致的方式處理檢體並得出結果的分子診斷平台、多重檢測檢測法以及先進的數據管理系統，以減少人為操作差異並提高操作一致性。監管機構對捐血安全、病原體監測、記錄和品質保證的期望不斷推動標準化檢測演算法和可靠檢驗技術的開發。同時，包括蟲媒病毒和具有公共衛生影響的呼吸道病原體在內的新發和再發感染疾病的威脅，進一步凸顯了高度適應性篩檢計畫的重要性，這些計畫能夠根據不斷變化的流行病學風險整合新的檢測方法。醫療衛生系統正在優先考慮分散式檢體採集、加強低溫運輸整合、基於條碼的可追溯性以及檢查室和臨床系統之間的互通性。這些變化在保持循證檢驗和訓練有素的檢查室人員監督等核心要求的同時，使血液篩檢更具可預測性、擴充性和快速響應能力，能夠更好地滿足日常醫療需求和應對公共衛生突發事件。

人工智慧對血液篩檢的累積影響

人工智慧 (AI) 正透過最佳化工作流程、影像分析、異常檢測、捐血風險評估和檢查室品管等方式，逐步影響血液篩檢。 AI 驅動的決策支援可以幫助確定檢體優先順序、識別偵測瓶頸、精確定位不一致的結果，並在高通量環境下更有效地分配資源。在血液學和形態學工作流程中，機器學習工具可以輔助模式識別和分診，而先進的分析技術可以透過識別不利事件、捐血排除和感染標記反應的趨勢來增強血液警戒。 AI 還可以透過使篩檢能力與血液供應需求相匹配，幫助進行實驗室設備的預測性維護並改善庫存規劃。然而，AI 的應用需要檢驗的演算法、透明的效能指標、網路安全措施、偏差監測、監管部門的批准以及人工監督。因此，AI 的累積影響並非在於取代檢查室專業知識，而是在於提高血庫、參考檢查室和整個綜合醫療保健網路篩檢的準確性、可追溯性、週轉時間和營運彈性。

關於血液篩檢的關鍵區域見解

亞太地區的特點是醫療衛生體系多元化、病患數量龐大、診斷基礎設施不斷完善，以及對血液安全現代化持續投入。該地區各國正在加強自願捐血計畫、篩檢並提升分子檢測能力，同時都市區醫院網路也越來越依賴自動化來應對日益成長的檢測量。歐洲受益於區域血液和組織安全框架、統一的安全標準、完善的血液供給機構、高水準的合規性監測，以及對可追溯性、捐血保護和循證篩檢方案的高度重視。北美擁有成熟的血液篩檢環境，這得益於嚴格的法律規範、先進的檢查室自動化、核酸檢測的廣泛應用以及健全的血液警戒措施，並持續關注捐血安全、應對新發病原體、數位化可追溯性和持續的品質改進。在拉丁美洲，血液篩檢正透過國家血液服務、區域品質改進舉措以及傳染病檢查能力的提升而不斷發展，但都市區地區的醫療資源和基礎設施存在差異。在非洲，優先事項仍是擴大篩檢覆蓋範圍、加強國家輸血服務、控制感染疾病以及招募捐血，國際衛生指南支持提高檢測品質、保障血液供應可靠性以及加強檢查室能力建設。在中東，正在投資醫院現代化、建造集中式檢查室網路和血庫認證，日益重視輸血安全、分子診斷和綜合臨床實驗室系統。

血液篩檢的關鍵群體分析

許多北約成員國擁有先進的醫療保健系統，並將建立具有韌性的醫療保健供應鏈、實現醫療保健系統互通、確保血液供應可靠以及具備應對民用和國防相關醫療需求的緊急應變能力作為戰略重點。七國集團（G7）國家普遍擁有先進的檢查室自動化技術、健全的法規結構、成熟的捐血篩檢方案、品質保證的輸血實踐以及應對新發感染疾病風險的充分準備。金磚國家的情況複雜多樣，但影響深遠，它們既面臨著大規模的公共衛生需求，又在不斷擴大診斷設備製造規模，引入了分子檢測技術，推行了國家血液安全舉措，並致力於改善不同醫療保健基礎設施之間的公平獲取。歐盟的特點是監管原則協調一致，對跨境安全、可追溯性要求、捐血保護措施以及對血液機構品管的持續投入。在東協地區，協調不同醫療保健系統之間的品質標準，同時促進可靠檢測、自願捐血、集中式血液服務模式以及檢查室人員能力建設，這些因素共同塑造了血液篩檢的優先事項。海灣合作理事會（GCC）國家正著力推動先進的醫院基礎設施、認證的檢查室操作規範、國家數位健康戰略以及血庫現代化，這些措施有助於提升輸血安全性並加速採用自動化篩檢技術。該集團的核心關注點在於品質標準化、捐血安全、感染疾病防治、數位化可追溯性以及建立穩健的血液系統。

主要國家血液篩檢趨勢

中國正透過醫院現代化、引進分子診斷、加強品管以及持續發展集中化和本地化的血液服務，不斷提升血液篩檢能力。美國擁有世界上最先進的血液篩檢體系之一，其特點是嚴格的捐血合格標準、廣泛應用傳染病篩檢、核酸檢測、法律規範以及成熟的血液警戒系統。日本和韓國擁有技術先進的檢測系統、高標準的品質規範，並積極採用自動化診斷技術。印度則致力於在其龐大而多元化的醫療保健網路中提高篩檢的可及性，推廣自願捐血，並規範血庫、傳染病檢查和品質保證。德國、法國、義大利和西班牙擁有成熟的歐洲血液篩檢體系，該體係依賴於監管合規、自動化、成熟的輸血醫學專業知識和完善的血液警戒實踐。英國擁有嚴格的血液安全管治、集中化的指南、完善的捐血篩檢管理以及健全的血液警戒通報系統。同時，澳洲也受惠於協調的血液服務、嚴格的捐血篩檢以及完善的品質保證體系，這些都為其地域分散的人口提供了可靠的輸血安全保障。加拿大則強調全國的協調、捐血安全、檢查室品質以及血液系統的可追溯性。俄羅斯的血液篩檢環境受到覆蓋廣大地域的需求、其公共醫療基礎設施以及集中化安全要求的影響。巴西將大規模的輸血網路與持續的感染疾病監測和品質改進工作相結合，而墨西哥則透過公共衛生舉措、改善捐血篩檢以及檢查室工作流程的現代化來提升血液安全。

針對血液篩檢負責人的實用建議

行業領導者應優先考慮檢驗的自動化技術、可互通的實驗室資訊系統以及符合不斷變化的監管和公共衛生要求的基於風險的篩檢策略。投資於核酸檢測、多重檢測平台、品質管理計畫、員工培訓和能力評估可以提高準確性和營運韌性。血液中心和診斷檢查室應制定靈活的檢測實施流程，以應對新出現的感染疾病威脅，並將血液警戒資料整合到持續改善計畫中。隨著篩檢操作日益數位化，領導者需要加強網路安全、資料管治、基於條碼的可追溯性和稽核準備。與公共衛生機構、醫院、認證機構、捐血招募組織和輸血醫學專家進行策略合作可以提高供應可靠性和篩檢覆蓋率。在資源有限的環境下，分階段現代化、集中標準測試、人才培養、參與外部品質評估和標準化操作程序可以在不給基礎設施造成過重負擔的情況下，將輸血安全性提高到可衡量的水平。

調查方法

本執行摘要採用系統性的二手檢驗編寫，所用資料均來自公開可查的資訊來源，包括衛生部門指南、血液安全框架、監管文件、同行評審文獻、輸血醫學標準、檢查室品質研究途徑、認證要求和公共衛生出版物。分析重點關注與技術應用、監管方向、當地醫療基礎設施、傳染病篩檢實踐、捐血安全、檢查室自動化、血液警戒和數位轉型相關的定性證據。為了提高可靠性並避免依賴單一資訊來源，本研究對多個資訊來源類別的資訊進行檢驗驗證。本調查方法不涉及市場規模估算、收入預測、佔有率分析或前瞻性預測；而是專注於檢驗的行業趨勢、營運趨勢、政策影響以及基於證據的、對血液篩檢相關人員的策略啟示。

結論

血液篩檢正從一項核心安全功能演變為數位化互聯、智慧主導的現代醫療保健系統的重要組成部分。自動化、分子診斷、品質標準化、人工智慧驅動的分析、資料互通性以及應對新興感染疾病風險的準備工作，共同塑造這一領域的發展方向。儘管區域和國家層面仍存在顯著差異，尤其是在基礎設施成熟度、篩檢可及性、人才能力和監管協調方面，但全球發展方向是一致的：更安全的輸血實踐、更強的可追溯性、更快捷的檢測流程、更完善的血液監測以及更具韌性的血液系統。投資於檢驗技術、人才培養、互通性、網路安全和高度適應性品管系統的行業領導者，將更有能力保障患者安全、增強公共衛生應急能力並實現永續的血液篩檢績效。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 市場動態
  • 波特五力分析
  • PESTLE分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：人工智慧的累積影響，2026年

第7章 血液篩檢市場：依產品/服務分類

  • 裝置
  • 試劑和試劑盒
  • 控制和校準器
  • 軟體和資訊技術
  • 服務

第8章 血液篩檢市場：依檢測類型分類

  • 乙型肝炎篩檢
  • 丙型肝炎篩檢
  • 愛滋病毒篩檢
  • 梅毒篩檢

第9章 血液篩檢市場：依技術分類

  • 化學冷光
  • 流式細胞技術
  • 免疫測量
    • 化學冷光免疫檢測
    • 酵素免疫分析法（ELISA）
    • 免疫測量
  • 分子診斷
    • 等溫擴增
    • 次世代定序
    • 聚合酵素鏈鎖反應

第10章 血液篩檢市場：依樣本類型分類

  • 電漿
  • 血清
  • 全血

第11章 血液篩檢市場：依檢測方法分類

  • 實驗室基地
  • 照護現場

第12章 血液篩檢市場：依最終用戶分類

  • 血庫
  • 醫院和診所
  • 診斷檢查室

第13章 血液篩檢市場：依地區分類

  • 亞太地區
  • 歐洲
  • 北美洲
  • 拉丁美洲
  • 非洲
  • 中東

第14章 血液篩檢市場：依組別分類

  • NATO
  • G7
  • BRICS
  • EU
  • ASEAN
  • GCC

第15章 血液篩檢市場：依國家分類

  • 中國
  • 美國
  • 日本
  • 印度
  • 德國
  • 英國
  • 澳洲
  • 法國
  • 韓國
  • 義大利
  • 加拿大
  • 俄羅斯
  • 巴西
  • 墨西哥
  • 西班牙

第16章 競爭格局

  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年

第17章：公司簡介

  • Abbott Laboratories
  • Agena Bioscience, Inc.
  • Becton, Dickinson and Company
  • Bio-Rad Laboratories, Inc.
  • bioMerieux SA
  • Cerus Corporation
  • Danaher Corporation
  • DiaSorin SpA
  • F. Hoffmann-La Roche Ltd
  • Fresenius Kabi AG
  • Grifols, SA
  • Haemonetics Corporation
  • Hologic, Inc.
  • Immucor, Inc.
  • Merck KGaA
  • Ortho Clinical Diagnostics, Inc.
  • QIAGEN NV
  • Quotient Suisse SA
  • Revvity, Inc.
  • Siemens Healthineers AG
  • Sysmex Corporation
  • Terumo BCT, Inc.
  • Thermo Fisher Scientific Inc.
  • Trinity Biotech plc
  • Tulip Diagnostics（P）Ltd.
  • Werfen SA
Product Code: MRR-374DB5A06BE3

The Blood Screening Market is projected to grow by USD 6.50 billion at a CAGR of 9.07% by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 3.54 billion
Estimated Year [2026] USD 3.85 billion
Forecast Year [2032] USD 6.50 billion
CAGR (%) 9.07%

Blood Screening Executive Summary

Blood screening is a critical pillar of transfusion safety, infectious disease surveillance, prenatal care, oncology support, organ transplantation, and population health programs. The field spans serological testing, nucleic acid testing, immunohematology, hematology screening, molecular diagnostics, pathogen reduction support, and donor eligibility assessment. Demand is shaped by the continuing need to prevent transfusion-transmitted infections, improve early disease detection, strengthen blood bank quality systems, and support resilient healthcare infrastructure. Key industry priorities include faster turnaround time, higher analytical sensitivity, automation of high-volume workflows, standardized quality control, and compliance with evolving regulatory and accreditation requirements. Blood screening programs are also increasingly linked to digital health records, laboratory information systems, donor management platforms, and public health reporting networks, creating a more connected ecosystem for traceability, hemovigilance, and risk-based decision-making. Public health guidance from global and national authorities consistently identifies safe, quality-assured blood and blood components as essential to healthcare delivery, reinforcing the strategic importance of reliable blood screening across hospitals, blood centers, and diagnostic laboratories.

Transformative Shifts in the Blood Screening Landscape

The blood screening landscape is undergoing a structural shift from reactive testing toward integrated, risk-based, and digitally enabled screening models. Laboratories and blood centers are adopting automated analyzers, sample-to-answer molecular platforms, multiplex assays, and enhanced data management systems to reduce manual variation and improve operational consistency. Regulatory expectations around donor safety, pathogen surveillance, documentation, and quality assurance continue to encourage standardized testing algorithms and robust validation practices. At the same time, emerging and re-emerging infectious threats, including arboviruses and respiratory pathogens with public health implications, have reinforced the importance of adaptable screening programs that can incorporate new assays when epidemiological risks change. Healthcare systems are also prioritizing decentralized sample collection, improved cold chain coordination, barcode-enabled traceability, and interoperability between laboratory and clinical systems. These shifts are making blood screening more predictive, scalable, and responsive to both routine healthcare needs and public health emergencies, while maintaining the central requirement for evidence-based validation and trained laboratory oversight.

Cumulative Impact of Artificial Intelligence on Blood Screening

Artificial intelligence is beginning to influence blood screening through workflow optimization, image interpretation, anomaly detection, predictive donor risk assessment, and laboratory quality management. AI-enabled decision support can help prioritize samples, identify testing bottlenecks, flag inconsistent results, and support more efficient resource allocation in high-throughput environments. In hematology and morphology workflows, machine learning tools can assist with pattern recognition and triage, while advanced analytics can strengthen hemovigilance by identifying trends in adverse events, donor deferrals, and infectious marker reactivity. AI also supports predictive maintenance for laboratory instruments and can improve inventory planning by linking screening capacity with blood supply needs. However, adoption depends on validated algorithms, transparent performance metrics, cybersecurity safeguards, bias monitoring, regulatory acceptance, and human oversight. The cumulative impact of AI is therefore not the replacement of laboratory expertise, but the augmentation of screening accuracy, traceability, turnaround time, and operational resilience across blood banks, reference laboratories, and integrated healthcare networks.

Key Regional Insights for Blood Screening

Asia-Pacific is marked by diverse healthcare systems, large patient populations, expanding diagnostic infrastructure, and sustained investment in blood safety modernization. Countries across the region are strengthening voluntary blood donation systems, screening coverage, and molecular testing capabilities, while urban hospital networks increasingly rely on automation to manage rising procedure volumes. Europe benefits from harmonized safety expectations, well-established blood establishments, high levels of compliance monitoring, and strong emphasis on traceability, donor protection, and evidence-based screening protocols under regional blood and tissue safety frameworks. North America has a mature blood screening environment supported by stringent regulatory oversight, advanced laboratory automation, broad adoption of nucleic acid testing, and strong hemovigilance practices, with continued focus on donor safety, emerging pathogen readiness, digital traceability, and continuous quality improvement. Latin America is advancing blood screening through national blood services, regional quality initiatives, and improved infectious disease testing, although access and infrastructure can vary across urban and rural settings. Africa continues to prioritize expanded screening access, strengthened national blood transfusion services, infectious disease control, and donor recruitment, with international health guidance supporting improvements in testing quality, supply reliability, and laboratory capacity. The Middle East is investing in hospital modernization, centralized laboratory networks, and blood bank accreditation, with increasing attention to transfusion safety, molecular diagnostics, and integrated clinical laboratory systems.

Key Group Insights for Blood Screening

NATO member countries, many of which overlap with advanced healthcare systems, place strategic emphasis on resilient medical supply chains, interoperable health systems, secure blood availability, and emergency preparedness for civilian and defense-related health needs. G7 countries generally demonstrate high levels of laboratory automation, robust regulatory frameworks, mature donor screening protocols, quality-assured transfusion medicine practices, and strong preparedness for emerging infectious disease risks. BRICS countries present a mixed but influential landscape, combining large-scale public health needs with expanding diagnostic manufacturing, molecular testing adoption, national blood safety initiatives, and efforts to improve equitable access across diverse healthcare infrastructures. The European Union is defined by coordinated regulatory principles, cross-border safety expectations, traceability requirements, donor protection measures, and sustained investment in quality management across blood establishments. Within ASEAN, blood screening priorities are shaped by the need to harmonize quality standards across varied healthcare systems while improving access to reliable testing, voluntary donation, centralized blood service models, and laboratory workforce capability. GCC countries are emphasizing advanced hospital infrastructure, accreditation-driven laboratory practices, national digital health strategies, and blood bank modernization, supporting stronger transfusion safety and rapid adoption of automated screening technologies. Across these groups, the central themes are quality standardization, donor safety, infectious disease readiness, digital traceability, and resilient blood system performance.

Key Country Insights for Blood Screening

China is expanding blood screening capacity through hospital modernization, molecular diagnostics adoption, stronger quality controls, and continued development of centralized and regionalized blood services. The United States has one of the most advanced blood screening ecosystems, characterized by stringent donor eligibility rules, broad use of infectious disease screening, nucleic acid testing, regulatory oversight, and mature hemovigilance systems. Japan and South Korea maintain technologically advanced laboratory systems, high-quality standards, and strong adoption of automated diagnostics, while India is focused on improving screening access, voluntary donation, blood bank standardization, infectious disease testing, and quality assurance across a large and diverse healthcare network. Germany, France, Italy, and Spain operate mature European blood screening systems supported by regulatory compliance, automation, established transfusion medicine expertise, and well-developed hemovigilance practices. The United Kingdom maintains rigorous blood safety governance, centralized guidance, donor screening controls, and strong hemovigilance reporting, while Australia benefits from coordinated blood services, strict donor screening, and established quality assurance systems that support reliable transfusion safety across a geographically dispersed population. Canada emphasizes national coordination, donor safety, laboratory quality, and traceability across its blood system. Russia's blood screening environment is influenced by large geographic coverage needs, public healthcare infrastructure, and centralized safety requirements. Brazil combines a large transfusion network with ongoing infectious disease surveillance and quality improvement efforts, while Mexico is strengthening blood safety through public health initiatives, improved donor screening, and modernization of laboratory workflows.

Actionable Recommendations for Blood Screening Leaders

Industry leaders should prioritize validated automation, interoperable laboratory information systems, and risk-based screening strategies that align with evolving regulatory and public health requirements. Investment in nucleic acid testing, multiplex platforms, quality control programs, staff training, and competency assessment can strengthen accuracy and operational resilience. Blood centers and diagnostic laboratories should develop flexible assay adoption pathways to respond to emerging infectious threats and should integrate hemovigilance data into continuous improvement programs. Leaders should also enhance cybersecurity, data governance, barcode-enabled traceability, and audit readiness as screening workflows become more digital. Strategic collaboration with public health agencies, hospitals, accreditation bodies, donor recruitment organizations, and transfusion medicine experts can improve supply reliability and screening coverage. In resource-constrained settings, phased modernization, centralized reference testing, workforce development, external quality assessment participation, and standardized operating procedures can deliver measurable improvements in transfusion safety without overextending infrastructure.

Research Methodology

This executive summary is developed through a structured secondary research approach using publicly available and verifiable sources such as health authority guidance, blood safety frameworks, regulatory documents, peer-reviewed literature, transfusion medicine standards, laboratory quality guidelines, accreditation requirements, and public health publications. The analysis focuses on qualitative evidence related to technology adoption, regulatory direction, regional healthcare infrastructure, infectious disease screening practices, donor safety, laboratory automation, hemovigilance, and digital transformation. Insights are triangulated across multiple source categories to improve reliability and avoid dependence on a single information stream. The methodology excludes market sizing, revenue estimation, share analysis, or forecasting and instead emphasizes verified industry dynamics, operational trends, policy influences, and evidence-based strategic implications for blood screening stakeholders.

Conclusion

Blood screening is evolving from a core safety function into a digitally connected, intelligence-driven component of modern healthcare systems. The sector's direction is shaped by automation, molecular diagnostics, quality standardization, AI-enabled analytics, data interoperability, and preparedness for emerging infectious risks. Regional and country-level differences remain significant, particularly in infrastructure maturity, screening access, workforce capacity, and regulatory alignment, but the global trajectory is consistent: safer transfusion practices, stronger traceability, faster testing workflows, better hemovigilance, and more resilient blood systems. Industry leaders that invest in validated technology, workforce capability, interoperability, cybersecurity, and adaptive quality systems will be best positioned to support patient safety, public health readiness, and sustainable blood screening performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. New Revenue Opportunities
  • 3.5. Next-Generation Business Models
  • 3.6. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Market Dynamics
    • 4.3.1. Key Drivers
    • 4.3.2. Key Restraints
    • 4.3.3. Key Opportunities
    • 4.3.4. Key Challenges
  • 4.4. Porter's Five Forces Analysis
  • 4.5. PESTLE Analysis
  • 4.6. Market Outlook
    • 4.6.1. Near-Term Market Outlook (0-2 Years)
    • 4.6.2. Medium-Term Market Outlook (3-5 Years)
    • 4.6.3. Long-Term Market Outlook (5-10 Years)
  • 4.7. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Blood Screening Market, by Offering

  • 7.1. Introduction
  • 7.2. Instruments
  • 7.3. Reagents & Kits
  • 7.4. Controls & Calibrators
  • 7.5. Software & Informatics
  • 7.6. Services

8. Blood Screening Market, by Test Type

  • 8.1. Introduction
  • 8.2. Hepatitis B Screening
  • 8.3. Hepatitis C Screening
  • 8.4. HIV Screening
  • 8.5. Syphilis Screening

9. Blood Screening Market, by Technology

  • 9.1. Introduction
  • 9.2. Chemiluminescence
  • 9.3. Flow Cytometry
  • 9.4. Immunoassays
    • 9.4.1. Chemiluminescence Immunoassay
    • 9.4.2. Enzyme Linked Immunosorbent Assay
    • 9.4.3. Radioimmunoassay
  • 9.5. Molecular Diagnostics
    • 9.5.1. Isothermal Amplification
    • 9.5.2. Next Generation Sequencing
    • 9.5.3. Polymerase Chain Reaction

10. Blood Screening Market, by Sample Type

  • 10.1. Introduction
  • 10.2. Plasma
  • 10.3. Serum
  • 10.4. Whole Blood

11. Blood Screening Market, by Testing Mode

  • 11.1. Introduction
  • 11.2. Lab Based
  • 11.3. Point Of Care

12. Blood Screening Market, by End User

  • 12.1. Introduction
  • 12.2. Blood Banks
  • 12.3. Hospitals & Clinics
  • 12.4. Diagnostic Laboratories

13. Blood Screening Market, by Region

  • 13.1. Asia-Pacific
  • 13.2. Europe
  • 13.3. North America
  • 13.4. Latin America
  • 13.5. Africa
  • 13.6. Middle East

14. Blood Screening Market, by Group

  • 14.1. NATO
  • 14.2. G7
  • 14.3. BRICS
  • 14.4. European Union
  • 14.5. ASEAN
  • 14.6. GCC

15. Blood Screening Market, by Country

  • 15.1. China
  • 15.2. United States
  • 15.3. Japan
  • 15.4. India
  • 15.5. Germany
  • 15.6. United Kingdom
  • 15.7. Australia
  • 15.8. France
  • 15.9. South Korea
  • 15.10. Italy
  • 15.11. Canada
  • 15.12. Russia
  • 15.13. Brazil
  • 15.14. Mexico
  • 15.15. Spain

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2025
  • 16.2. FPNV Positioning Matrix, 2025
  • 16.3. Market Concentration Analysis, 2025
    • 16.3.1. Concentration Ratio (CR)
    • 16.3.2. Herfindahl Hirschman Index (HHI)
  • 16.4. Recent Developments & Impact Analysis, 2025
  • 16.5. Product Portfolio Analysis, 2025
  • 16.6. Benchmarking Analysis, 2025

17. Company Profiles

  • 17.1. Abbott Laboratories
  • 17.2. Agena Bioscience, Inc.
  • 17.3. Becton, Dickinson and Company
  • 17.4. Bio-Rad Laboratories, Inc.
  • 17.5. bioMerieux SA
  • 17.6. Cerus Corporation
  • 17.7. Danaher Corporation
  • 17.8. DiaSorin S.p.A.
  • 17.9. F. Hoffmann-La Roche Ltd
  • 17.10. Fresenius Kabi AG
  • 17.11. Grifols, S.A.
  • 17.12. Haemonetics Corporation
  • 17.13. Hologic, Inc.
  • 17.14. Immucor, Inc.
  • 17.15. Merck KGaA
  • 17.16. Ortho Clinical Diagnostics, Inc.
  • 17.17. QIAGEN N.V.
  • 17.18. Quotient Suisse SA
  • 17.19. Revvity, Inc.
  • 17.20. Siemens Healthineers AG
  • 17.21. Sysmex Corporation
  • 17.22. Terumo BCT, Inc.
  • 17.23. Thermo Fisher Scientific Inc.
  • 17.24. Trinity Biotech plc
  • 17.25. Tulip Diagnostics (P) Ltd.
  • 17.26. Werfen S.A.

LIST OF FIGURES

  • FIGURE 1. GLOBAL BLOOD SCREENING MARKET, YEARS CONSIDERED FOR THE STUDY
  • FIGURE 2. GLOBAL BLOOD SCREENING MARKET, RESEARCH DESIGN
  • FIGURE 3. GLOBAL BLOOD SCREENING MARKET, RESEARCH FRAMEWORK
  • FIGURE 4. GLOBAL BLOOD SCREENING MARKET, DATA TRIANGULATION
  • FIGURE 5. GLOBAL BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 6. GLOBAL BLOOD SCREENING MARKET SIZE, BY OFFERING, 2025 VS 2032 (%)
  • FIGURE 7. GLOBAL BLOOD SCREENING MARKET SIZE, BY OFFERING, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2032 (%)
  • FIGURE 9. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2032 (%)
  • FIGURE 11. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2032 (%)
  • FIGURE 13. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 14. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025 VS 2032 (%)
  • FIGURE 15. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 16. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2025 VS 2032 (%)
  • FIGURE 17. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 18. GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2025 VS 2032 (%)
  • FIGURE 19. GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 20. GLOBAL BLOOD SCREENING MARKET SIZE, BY GROUP, 2025 VS 2032 (%)
  • FIGURE 21. GLOBAL BLOOD SCREENING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2032 (%)
  • FIGURE 23. GLOBAL BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 24. GLOBAL BLOOD SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 25. GLOBAL BLOOD SCREENING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025

LIST OF TABLES

  • TABLE 1. GLOBAL BLOOD SCREENING MARKET SEGMENTATION & COVERAGE
  • TABLE 2. GLOBAL BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL INSTRUMENTS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL INSTRUMENTS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL INSTRUMENTS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL REAGENTS & KITS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL REAGENTS & KITS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL REAGENTS & KITS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL CONTROLS & CALIBRATORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL CONTROLS & CALIBRATORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL CONTROLS & CALIBRATORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL SOFTWARE & INFORMATICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL SOFTWARE & INFORMATICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL SOFTWARE & INFORMATICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL SERVICES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL SERVICES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL SERVICES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL HEPATITIS B SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL HEPATITIS B SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL HEPATITIS B SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL HEPATITIS C SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL HEPATITIS C SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL HEPATITIS C SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL HIV SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL HIV SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL HIV SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL SYPHILIS SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL SYPHILIS SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL SYPHILIS SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL CHEMILUMINESCENCE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL FLOW CYTOMETRY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMMUNOASSAYS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMMUNOASSAYS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMMUNOASSAYS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL CHEMILUMINESCENCE IMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ENZYME LINKED IMMUNOSORBENT ASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL RADIOIMMUNOASSAY MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL RADIOIMMUNOASSAY MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL RADIOIMMUNOASSAY MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL MOLECULAR DIAGNOSTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ISOTHERMAL AMPLIFICATION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL NEXT GENERATION SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL POLYMERASE CHAIN REACTION MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL PLASMA MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL PLASMA MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL PLASMA MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL SERUM MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL SERUM MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL SERUM MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL WHOLE BLOOD MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL WHOLE BLOOD MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL WHOLE BLOOD MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL LAB BASED MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL LAB BASED MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL LAB BASED MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL POINT OF CARE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL POINT OF CARE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL POINT OF CARE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL BLOOD BANKS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL BLOOD BANKS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL BLOOD BANKS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL HOSPITALS & CLINICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL DIAGNOSTIC LABORATORIES MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL BLOOD SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 92. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 100. EUROPE BLOOD SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 101. EUROPE BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 102. EUROPE BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. EUROPE BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 104. EUROPE BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPE BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPE BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPE BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPE BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 109. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 111. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 114. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 115. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 117. NORTH AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 118. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 119. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 120. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 121. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 122. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 123. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 124. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 126. LATIN AMERICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 127. AFRICA BLOOD SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 128. AFRICA BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 129. AFRICA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. AFRICA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 131. AFRICA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 132. AFRICA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 133. AFRICA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. AFRICA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 135. AFRICA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 137. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 138. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 139. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 140. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 141. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 142. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 143. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 144. MIDDLE EAST BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 145. GLOBAL BLOOD SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 146. NATO BLOOD SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 147. NATO BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 148. NATO BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. NATO BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 150. NATO BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 151. NATO BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 152. NATO BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. NATO BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 154. NATO BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 155. G7 BLOOD SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 156. G7 BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 157. G7 BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 158. G7 BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 159. G7 BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 160. G7 BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 161. G7 BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 162. G7 BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 163. G7 BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 164. BRICS BLOOD SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 165. BRICS BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 166. BRICS BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 167. BRICS BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 168. BRICS BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 169. BRICS BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 170. BRICS BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 171. BRICS BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 172. BRICS BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 173. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 174. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 175. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 176. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 177. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 178. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 179. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 180. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 181. EUROPEAN UNION BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 182. ASEAN BLOOD SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 183. ASEAN BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 184. ASEAN BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 185. ASEAN BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 186. ASEAN BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 187. ASEAN BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 188. ASEAN BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. ASEAN BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 190. ASEAN BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 191. GCC BLOOD SCREENING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 192. GCC BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 193. GCC BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 194. GCC BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 195. GCC BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 196. GCC BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 197. GCC BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 198. GCC BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 199. GCC BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 200. GLOBAL BLOOD SCREENING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 201. CHINA BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 202. CHINA BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 203. CHINA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 204. CHINA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 205. CHINA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 206. CHINA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 207. CHINA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 208. CHINA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 209. CHINA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 210. UNITED STATES BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 211. UNITED STATES BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 212. UNITED STATES BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 213. UNITED STATES BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 214. UNITED STATES BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 215. UNITED STATES BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 216. UNITED STATES BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 217. UNITED STATES BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 218. UNITED STATES BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 219. JAPAN BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 220. JAPAN BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 221. JAPAN BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 222. JAPAN BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 223. JAPAN BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 224. JAPAN BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 225. JAPAN BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 226. JAPAN BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 227. JAPAN BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 228. INDIA BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 229. INDIA BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 230. INDIA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 231. INDIA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 232. INDIA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 233. INDIA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 234. INDIA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 235. INDIA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 236. INDIA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 237. GERMANY BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 238. GERMANY BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 239. GERMANY BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. GERMANY BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 241. GERMANY BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 242. GERMANY BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 243. GERMANY BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 244. GERMANY BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 245. GERMANY BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 246. UNITED KINGDOM BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 247. UNITED KINGDOM BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 248. UNITED KINGDOM BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 249. UNITED KINGDOM BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 250. UNITED KINGDOM BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 251. UNITED KINGDOM BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 252. UNITED KINGDOM BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 253. UNITED KINGDOM BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 254. UNITED KINGDOM BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 255. AUSTRALIA BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 256. AUSTRALIA BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 257. AUSTRALIA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 258. AUSTRALIA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 259. AUSTRALIA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 260. AUSTRALIA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 261. AUSTRALIA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 262. AUSTRALIA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 263. AUSTRALIA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 264. FRANCE BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 265. FRANCE BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 266. FRANCE BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 267. FRANCE BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 268. FRANCE BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 269. FRANCE BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 270. FRANCE BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 271. FRANCE BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 272. FRANCE BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 273. SOUTH KOREA BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 274. SOUTH KOREA BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 275. SOUTH KOREA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 276. SOUTH KOREA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 277. SOUTH KOREA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 278. SOUTH KOREA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 279. SOUTH KOREA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 280. SOUTH KOREA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 281. SOUTH KOREA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 282. ITALY BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 283. ITALY BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 284. ITALY BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 285. ITALY BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 286. ITALY BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 287. ITALY BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 288. ITALY BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 289. ITALY BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 290. ITALY BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 291. CANADA BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 292. CANADA BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 293. CANADA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 294. CANADA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 295. CANADA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 296. CANADA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 297. CANADA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 298. CANADA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 299. CANADA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. RUSSIA BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 301. RUSSIA BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 302. RUSSIA BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 303. RUSSIA BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 304. RUSSIA BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 305. RUSSIA BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 306. RUSSIA BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 307. RUSSIA BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 308. RUSSIA BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 309. BRAZIL BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 310. BRAZIL BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 311. BRAZIL BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 312. BRAZIL BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 313. BRAZIL BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 314. BRAZIL BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 315. BRAZIL BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 316. BRAZIL BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 317. BRAZIL BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 318. MEXICO BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 319. MEXICO BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 320. MEXICO BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 321. MEXICO BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 322. MEXICO BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 323. MEXICO BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 324. MEXICO BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 325. MEXICO BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 326. MEXICO BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 327. SPAIN BLOOD SCREENING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 328. SPAIN BLOOD SCREENING MARKET SIZE, BY OFFERING, 2018-2032 (USD MILLION)
  • TABLE 329. SPAIN BLOOD SCREENING MARKET SIZE, BY TEST TYPE, 2018-2032 (USD MILLION)
  • TABLE 330. SPAIN BLOOD SCREENING MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 331. SPAIN BLOOD SCREENING MARKET SIZE, BY IMMUNOASSAYS, 2018-2032 (USD MILLION)
  • TABLE 332. SPAIN BLOOD SCREENING MARKET SIZE, BY MOLECULAR DIAGNOSTICS, 2018-2032 (USD MILLION)
  • TABLE 333. SPAIN BLOOD SCREENING MARKET SIZE, BY SAMPLE TYPE, 2018-2032 (USD MILLION)
  • TABLE 334. SPAIN BLOOD SCREENING MARKET SIZE, BY TESTING MODE, 2018-2032 (USD MILLION)
  • TABLE 335. SPAIN BLOOD SCREENING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 336. GLOBAL BLOOD SCREENING MARKET SHARE, BY KEY PLAYER, 2025
  • TABLE 337. GLOBAL BLOOD SCREENING MARKET, FPNV POSITIONING MATRIX, BY KEY PLAYER, 2025